Abstract
Over-expression of endosialin/CD248 (herein referred to as CD248) has been associated with increased tumor microvasculature in various tissue origins which makes it an attractive anti-angiogenic target. In an effort to target CD248, we have generated a human CD248 knock-in mouse line and MORAb-004, the humanized version of the mouse anti-human CD248 antibody Fb5. Here, we report that MORAb-004 treatment significantly impacted syngeneic tumor growth and tumor metastasis in the human CD248 knock-in mice. In comparison with untreated tumors, MORAb-004 treated tumors displayed overall shortened and distorted blood vessels. Immunofluorescent staining of tumor sections revealed drastically more small and dysfunctional vessels in the treated tumors. The CD248 levels on cell surfaces of neovasculature pericytes were significantly reduced due to its internalization. This reduction of CD248 was also accompanied by reduced α-SMA expression, depolarization of pericytes and endothelium, and ultimately dysfunctional microvessels. These results suggest that MORAb-004 reduced CD248 on pericytes, impaired tumor microvasculature maturation and ultimately suppressed tumor development.
References
Nov 15, 1992·Proceedings of the National Academy of Sciences of the United States of America·W J RettigL J Old
Jun 13, 1998·The Journal of Cell Biology·K K HirschiP A D'Amore
Aug 19, 2000·Science·B St CroixK W Kinzler
Apr 17, 2004·Cancer Research·Masao FuruhashiArne Ostman
Feb 24, 2006·Proceedings of the National Academy of Sciences of the United States of America·Akash NandaDavid L Huso
Aug 8, 2007·Journal of Vascular Surgery·Omaida C Velazquez
Jul 31, 2007·Cellular Signalling·Katherine HolmesMichael J Cross
Nov 8, 2007·Proceedings of the National Academy of Sciences of the United States of America·Brian TomkowiczYuhong Zhou
Jan 12, 2008·The American Journal of Pathology·Sven ChristianHellmut G Augustin
May 21, 2008·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·Renate BeckerSven Christian
Aug 2, 2008·The Journal of Biological Chemistry·Qiang DingMitchell A Olman
May 21, 2010·Cancer Biology & Therapy·Brian TomkowiczYuhong Zhou
Nov 9, 2011·Nature Medicine·Sara M Weis, David A Cheresh
Dec 31, 2011·Current Drug Targets·Yanet ValdezEdward M Conway
Nov 13, 2012·The American Journal of Pathology·Ching-Fang WuShuei-Liong Lin
Citations
Feb 26, 2016·Oncotarget·Sara E S LangeBrian A Van Tine
Aug 6, 2016·Oncotarget·Daniel J O'ShannessyNicholas C Nicolaides
Aug 27, 2016·Oncotarget·Poonam NagpalK Stephen Suh
Jun 24, 2017·Journal of Molecular Histology·Wen CaoXiang Ma
Nov 12, 2017·Investigational New Drugs·Sandra P D'AngeloRichard D Carvajal
Jul 2, 2019·Molecular Medicine Reports·Paola Di BenedettoPaola Cipriani
Apr 5, 2017·EMBO Molecular Medicine·Carolin MoglerHellmut G Augustin
Feb 2, 2018·Frontiers in Immunology·Carlos Cuesta-MateosCecilia Muñoz-Calleja
Jan 27, 2019·Scientific Reports·Chiara BarozziNazzareno Galiè
Jan 10, 2019·Investigational New Drugs·Toshihiko DoiRyo Nakajima
Jan 30, 2020·Molecular Imaging and Biology : MIB : the Official Publication of the Academy of Molecular Imaging·Francesco CiconeJohn O Prior
May 26, 2017·Neuro-oncology·Sadhana JacksonMark R Gilbert
Sep 28, 2017·Oncotarget·Emily CaponeGianluca Sala
Apr 30, 2019·Cancer·Robin L JonesRobert G Maki
Jul 10, 2019·The FEBS Journal·Kabir A KhanRoy Bicknell
Oct 5, 2018·Arthritis Research & Therapy·Paola Di BenedettoRoberto Giacomelli
Mar 9, 2019·Oncotarget·Beverly A Teicher
Nov 1, 2017·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Axel GrotheyLuis Alberto Diaz
Sep 17, 2016·Cancer Research·Carmen ViskiHellmut G Augustin
Jun 29, 2021·Frontiers in Cell and Developmental Biology·Ruipu SunPing-Pui Wong
Sep 2, 2021·Cell Reports Medicine·Julie K FierleSteven M Dunn